Telbivudine-Induced Myopathy: Clinical Features, Histopathological Characteristics, and Risk Factors
Open Access
- 1 January 2023
- journal article
- research article
- Published by Korean Neurological Association in Journal of Clinical Neurology
- Vol. 19 (1) , 52-59
Abstract
Lan MY, et al. J Clin Neurol. 2023 Jan;19(1):52-59. https://doi.org/10.3988/jcn.2023.19.1.52Keywords
Funding Information
- Chang Gung Memorial Hospital (CMRPG8J0991)
This publication has 39 references indexed in Scilit:
- Dysphagia could be the first presenting symptom of telbivudine‐induced myopathyInternal Medicine Journal, 2013
- Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis BClinical and Molecular Hepatology, 2013
- Minimization of hepatitis B infection by a 25-year universal vaccination programJournal of Hepatology, 2012
- Rhabdomyolysis in a 48-Year-Old Man With Hepatitis B-Induced CirrhosisThe American Journal of the Medical Sciences, 2011
- Clinical features and risk factors of creatine kinase elevations and myopathy associated with telbivudineJournal of Viral Hepatitis, 2010
- Myotoxicity of telbivudine in pre-existing muscle damageVirology Journal, 2010
- TelbivudineDrugs, 2007
- Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B.Journal of Clinical Investigation, 1997
- Mitochondrial Myopathy Caused by Long-Term Zidovudine TherapyNew England Journal of Medicine, 1990
- Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984: A study just before mass hepatitis B vaccination program in TaiwanJournal of Medical Virology, 1986